Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) CFO Sells $519,300.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CFO Nicole Labrosse sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $51.93, for a total transaction of $519,300.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares in the company, valued at $803,876.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Halozyme Therapeutics Trading Up 1.4 %

Shares of HALO opened at $52.36 on Monday. Halozyme Therapeutics, Inc. has a twelve month low of $32.83 and a twelve month high of $53.00. The firm has a market capitalization of $6.66 billion, a P/E ratio of 21.64, a price-to-earnings-growth ratio of 0.53 and a beta of 1.28. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. The stock’s fifty day simple moving average is $45.31 and its 200 day simple moving average is $40.45.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The company had revenue of $195.88 million for the quarter, compared to the consensus estimate of $201.72 million. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on HALO shares. HC Wainwright restated a “buy” rating and set a $65.00 price objective on shares of Halozyme Therapeutics in a research report on Monday, June 24th. Piper Sandler lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price objective for the company from $48.00 to $51.00 in a research report on Friday, June 7th. Benchmark upped their price objective on shares of Halozyme Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday, June 7th. Finally, JMP Securities reduced their price target on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 8th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average price target of $57.25.

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors have recently bought and sold shares of the business. TD Asset Management Inc increased its holdings in Halozyme Therapeutics by 517.0% in the 4th quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock valued at $73,326,000 after purchasing an additional 1,662,390 shares in the last quarter. Norges Bank acquired a new position in Halozyme Therapeutics during the 4th quarter worth approximately $44,935,000. Epoch Investment Partners Inc. boosted its holdings in Halozyme Therapeutics by 250.5% in the 4th quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock worth $42,986,000 after acquiring an additional 831,199 shares during the period. Boston Partners boosted its holdings in Halozyme Therapeutics by 562.2% in the 4th quarter. Boston Partners now owns 552,392 shares of the biopharmaceutical company’s stock worth $20,218,000 after acquiring an additional 468,977 shares during the period. Finally, LSV Asset Management acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $17,090,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.